Peer-reviewed veterinary case report
BIO drug reduces growth and spread of dog melanoma cells
By Chon, Esther et al.·Published in Veterinary journal (London, England : 1997)·2015·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: 6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.
- Species:
- dog
Plain-English summary
A study looked at how a new treatment called 6-bromoindirubin-3'-oxime (BIO) affects melanoma cells in dogs. Melanoma is a serious type of skin cancer that can be aggressive and hard to treat. In the lab, BIO was found to slow down the growth and movement of these cancer cells, which could be promising for future treatments. However, it didn't seem to affect the cells' ability to invade other tissues or cause cell death. This research suggests that targeting specific proteins in cancer cells might help improve treatment options for dogs with melanoma.
People also search for: dog melanoma treatment · canine skin cancer · 6-bromoindirubin-3'-oxime for dogs
Abstract
Despite recent therapeutic advances, malignant melanoma is an aggressive tumor in dogs and is associated with a poor outcome. Novel, targeted agents are necessary to improve survival. In this study, 6-bromoindirubin-3'-oxime (BIO), a serine/threonine kinase inhibitor with reported specificity for glycogen synthase kinase-3 beta (GSK-3β) inhibition, was evaluated in vitro in three canine melanoma cell lines (CML-10C2, UCDK9M2, and UCDK9M3) for β-catenin-mediated transcriptional activity, Axin2 gene and protein expression levels, cell proliferation, chemotoxicity, migration and invasion assays. BIO treatment of canine malignant melanoma cell lines at 5 µM for 72 h enhanced β-catenin-mediated transcriptional activity, suggesting GSK-3β inhibition, and reduced cell proliferation and migration. There were no significant effects on invasion, chemotoxicity, or apoptosis. The results suggest that serine/threonine kinases may be viable therapeutic targets for the treatment of canine malignant melanoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25130776/